Vulnerabilities Older Adults Impact Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Outcomes
Rachel Gorham(Vanderbilt University Medical Center), Reena Jayani(Vanderbilt University Medical Center), Nancy Clayton Long(Vanderbilt University Medical Center), Harvey J. Murff(Brigham and Women's Hospital), Olalekan O. Oluwole(Vanderbilt University), Adetola A. Kassim(Vanderbilt University), Andrew Jallouk(Vanderbilt University Medical Center), Bhagirathbhai Dholaria(Vanderbilt University Medical Center), Andrea Stafford Hintz(Vanderbilt University Medical Center), Melissa Logue(Vanderbilt University Medical Center), Hina Budhwani(Vanderbilt University Medical Center), Brittney Baer(Vanderbilt University Medical Center), Bipin N. Savani(Vanderbilt University Medical Center), Parul Mani Goyal(Vanderbilt University Medical Center), Eden Biltibo(Vanderbilt University Medical Center)
Cited by 0
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782